Hematology Diagnostics Market Size is expected to reach USD 8.50 Billion, at a CAGR of 5%Â forecast period 2020-2027Hematology is the branch of science that deals with cause, prognosis, treatment, and prevention of blood disorders. The hematology diagnostics market is expected to witness tremendous growth owing to the rising prevalence of blood disorders and technological advancements. The Leukemia & Lymphoma Society (LLS)Â predicted 174,250 new cases of leukemia, lymphoma or myeloma in 2018 in the U.S. Other key factors like increase in the prevalence of genetic diseases, the rise in hematological testing, growing blood transfusions and donations and increasing adoption of automated hematology analyzers are contributing towards the growth of the hematology diagnostics market. According to the Centers for Disease Control and Prevention in 2017, approximately 70,000 to 100,000 Americans have sickle cell disease which is genetic blood disorder.
However, factors such as high cost of diagnostics, poor healthcare insurance coverage for diagnostic procedures and lack of awareness are expected to restrict the hematology diagnostics market growth during the forecast period.
Segmentation
The hematology diagnostics market is segmented on the basis of product type, tests, and end-user. The hematology diagnostics market, by product type categorized into hematology analyzers, flow cytometers, and consumables. Hematology analyzers category includes fully-automated hematology analyzers and semi-automated hematology analyzers. Consumables segment includes reagents, stains, controls & calibrators, and others. Tests category is further segmented into anemia, hemoglobinopathy, leukemia/lymphoma phenotyping, hematology pathophysiology, complete blood count (CBC) and others. On the basis of end-user, the hematology diagnostics market is segmented into hospitals and clinics, ambulatory surgical centers, diagnostic laboratories, academic institutes and others. Â
On the basis of region, the hematology diagnostics market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas is sub-segmented into North America and South America. The North American region is further segmented into the U.S. and Canada. The European region is divided into two, namely, Western Europe and Eastern Europe. Western Europe is further classified into Germany, Italy, France, the UK, Spain, and the rest of Western Europe. The Asia-Pacific region is sub-segmented into Japan, China, India, Australia, the Republic of Korea, and the rest of Asia-Pacific. The Middle Eastern and African region is sub-segmented into the United Arab Emirates, Saudi Arabia, Oman, Kuwait, Qatar, and the rest of the Middle East and Africa.
Regional Market Summary
Hematology Diagnostics Market Share (%), by Region, 2017
Sources: Â Statista, the Centers for Disease Control and Prevention, the World Hematology Congress, Leukemia & Lymphoma Society (LLS)
The hematology diagnostics market is dominated by North America owing to the rising prevalence of blood diseases. According to Statista in 2016, 33% of all the Americans were diagnosed with hemophilia A were between 19-44 years of age. The presence of major market players such as Abbott Laboratories Danaher, Bio-Rad Laboratories, and others within the region also influences the market growth. Other factors like increasing healthcare expenditure, technological advancements within the population drive the hematology diagnostics market growth in this region.
It is estimated that Europe stood second in the hematology diagnostics market owing to increasing hematology research within this region. The 16th World Hematology Congress will be conducted in March 2019 in London, UK to discuss the diagnosis and treatment of hematology, blood disorders, hematologic oncology, hematologic disorders, and immunohematology. Thus, increasing hematology research and government initiatives within this region influences the growth of hematology diagnostics market in this region.
Asia-Pacific was projected to be the fastest growing region for the hematology diagnostics market in 2017. The hematology diagnostics market is expected to witness growth owing to the rising prevalence of blood disorders and genetic diseases. The South Asians are more vulnerable to genetic disorders due to consanguineous marriages or marrying within the same ethnicity, community, caste, etc.Â
The Middle East and Africa holds the least share in the hematology diagnostics market due to the presence of stringent government policies and poor economies. However, the market is expected to witness growth due to high investments by the private market players in the Middle East. Also, the growing prevalence of genetic blood disorders and rising government initiatives to improve the healthcare sector within the region contribute to hematology diagnostics market growth.
Market Segmentation and Key Market Players
Hematology Diagnostics Market, by Product Type
Hematology Diagnostics Market, by Tests
Hematology Diagnostics Market, by End-User
Hematology Diagnostics Market, by Region
Hematology Diagnostics Market, by Key Players
Intended Audience
Report Attribute/Metric | Details |
---|---|
Market Size | 2027: USD 8.50 Billion |
CAGR | 5% (2020-2027) |
Base Year | 2019 |
Forecast Period | 2020-2027 |
Historical Data | 2018 |
Forecast Units | Value (USD Billion) |
Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
Segments Covered | Product Type, Tests, and End-user |
Geographies Covered | North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
Key Vendors | Sysmex (Japan), Danaher (US), Nihon Kohden (Japan), Siemens (Germany), Abbott Laboratories (US), Boule Diagnostics (Sweden), HORIBA (Japan), Bio-Rad Laboratories (US), BioSystems (Spain), Diatron (Hungary), Drew Scientific (US), EKF Diagnostics (UK), Mindray (China), Ortho Clinical Diagnostics (US), Roche (Switzerland) |
Key Market Opportunities |
|
Key Market Drivers |
|
Hematology Diagnostics Market is to reach at USD 8.50 Billion by 2027
Hematology Diagnostics Market is expected to register a CAGR of 5% during the forecast period of 2020 to 2027
key factors like increase in the prevalence of genetic diseases, the rise in hematological testing, growing blood transfusions and donations and increasing adoption of automated hematology analyzers are contributing towards the growth of the market.
The hematology diagnostics market is dominated by North America owing to the rising prevalence of blood diseases.
The central contenders in the hematology diagnostics market globally are Ortho Clinical Diagnostics (US), Danaher (US), Siemens (Germany), Boule Diagnostics (Sweden), HORIBA (Japan), Abbott Laboratories (US), EKF Diagnostics (UK), Bio-Rad Laboratories (US), BioSystems (Spain), Sysmex (Japan), Diatron (Hungary), Nihon Kohden (Japan), Drew Scientific (US), Mindray (China), and Roche (Switzerland), and other.